Celgene (CELG) Rising Before The Market Opens

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Celgene ( CELG) as a pre-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Celgene as such a stock due to the following factors:

CELG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $410.6 million.

CELG traded 12,795 shares today in the pre-market hours as of 9:25 AM.

CELG is up 2% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CELG with the Ticky from Trade-Ideas. See the FREE profile for CELG NOW at Trade-Ideas

More details on CELG:

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. CELG has a PE ratio of 54.2. Currently there are 18 analysts that rate Celgene a buy, no analysts rate it a sell, and 3 rate it a hold.

The average volume for Celgene has been 4.3 million shares per day over the past 30 days. Celgene has a market cap of $75.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.20 and a short float of 1.6% with 3.15 days to cover. Shares are up 9.1% year-to-date as of the close of trading on Monday.